86P Payload-driven fatal toxicity signals of antibody–drug conjugates in endometrial cancer: A FAERS disproportionality analysis

Antibody–drug conjugates (ADCs) have expanded therapeutic options in gynecologic malignancies, including endometrial cancer, but are associated with potentially serious and fatal toxicities. This study evaluates the association between ADCs and adverse event profiles, including fatal outcomes, using the FDA Adverse Event Reporting System.